Nanoliposomal irinotecan in the clinical practice guideline for metastatic pancreatic cancer: applicability to clinical situations.
Affiliation
Washington University School of Medicine, St. Louis, MOIssue Date
2016-12-05
Metadata
Show full item recordCitation
Nanoliposomal irinotecan in the clinical practice guideline for metastatic pancreatic cancer: applicability to clinical situations. 2016, J Clin OncolJournal
Journal of Clinical OncologyPubMed ID
27918719Type
ArticleLanguage
enISSN
1527-7755Collections
Related articles
- Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer.
- Authors: Ur Rehman SS, Lim K, Wang-Gillam A
- Issue date: 2016 May
- MM-398 (nanoliposomal irinotecan): emergence of a novel therapy for the treatment of advanced pancreatic cancer.
- Authors: Carnevale J, Ko AH
- Issue date: 2016 Feb
- Photodynamic Therapy Synergizes with Irinotecan to Overcome Compensatory Mechanisms and Improve Treatment Outcomes in Pancreatic Cancer.
- Authors: Huang HC, Mallidi S, Liu J, Chiang CT, Mai Z, Goldschmidt R, Ebrahim-Zadeh N, Rizvi I, Hasan T
- Issue date: 2016 Mar 1
- Development of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02) in the management of metastatic pancreatic cancer.
- Authors: Chiang NJ, Chang JY, Shan YS, Chen LT
- Issue date: 2016 Jul
- Best practices for the treatment of metastatic pancreatic adenocarcinoma: the therapeutic landscape in 2017.
- Authors: Cinar P, Ko AH
- Issue date: 2017 Jun